The FDA’s top drug regulator was placed on administrative leave after raising serious concerns about a controversial new approval process he claims circumvents decades of established scientific protocols and consolidates dangerous power in the hands of a single official.
Story Highlights
- Dr. George Tidmarsh, head of the FDA’s drug evaluation center, was placed on leave after questioning the new fast-track approval system.
- Tidmarsh claims retaliation for criticizing the process that gives one official control over all drug approvals.
- New system fast-tracks drugs for “companies aligned with critical U.S. national health priorities” using non-traditional methods.
- Top regulator calls current FDA environment “toxic” and harmful to the American people.
Top FDA Official Challenges New Drug Approval System
Dr. George Tidmarsh, who leads the FDA’s Center for Drug Evaluation and Research, was placed on administrative leave Friday after raising concerns about a new regulatory process designed to expedite drug approvals.
The system uses a tumor board-style review to fast-track approvals for companies deemed aligned with national health priorities, departing significantly from traditional FDA protocols that have governed drug safety for decades.
The Food and Drug Administration’s top drug regulator has resigned after being accused of soliciting a bribe and tanking a company’s stock as part of an alleged revenge plot against a former colleague. https://t.co/tm2esMU5wu
— The Daily Beast (@thedailybeast) November 3, 2025
Allegations of Retaliation Surface
Tidmarsh denies allegations of personal misconduct and claims his removal represents retaliation for speaking out against FDA Chief Medical Officer Vinay Prasad.
According to Tidmarsh, the new arrangement “circumvents rigorous scientific debate and puts Vinay Prasad in charge of every drug approval.” He described the process as fundamentally different from decades of established FDA precedent, raising serious questions about the integrity of drug safety oversight.
Constitutional Concerns Over Regulatory Authority
The controversy highlights broader concerns about regulatory overreach and the concentration of power within federal agencies. Tidmarsh’s criticism centers on the legality of bypassing traditional scientific review processes, suggesting the new system undermines the rigorous standards that protect American consumers from potentially dangerous medications.
This represents exactly the type of administrative state expansion that threatens constitutional governance and individual safety.
Toxic Environment Threatens Public Health
Tidmarsh’s characterization of the FDA as having a “toxic” environment should alarm every American concerned about government accountability. His statement that “anybody with a right mind would get out of a situation like that” suggests systemic problems within an agency responsible for protecting public health.
When career regulators flee rather than compromise their integrity, it signals deep institutional corruption that demands immediate attention from the Trump administration.
